News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 109–144
- Matches
- 623
- Sources here
- 22
- Companies here
- 14
Search results
Stored financial headlines
Active search
623 matching headlines
Ticker or company: SUMMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Reynolds Consumer Products Inc. (REYN) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of Reynolds Consumer Products Inc. (REYN), including its current stock price, dividend information, key financial metrics, performance comparison against the S&P 500, and analyst insights. The company specializes in packaging and containers, operating through four segments: …
REYN
main company
Sharemaestro market context
Trend signal active
52 weeks +15.6%
Reynolds Consumer Products Inc (REYN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Reynolds Consumer Products Inc (REYN), detailing its current earnings forecast score, analyst ratings, and price targets. It includes comparisons to peers and answers frequently asked questions regarding expected revenue, price targets, and past EPS performance. The current …
REYN
main company
Sharemaestro market context
Trend signal active
52 weeks +15.6%
Summit State Bank (SSBI) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Summit State Bank (SSBI), including future EPS and revenue growth estimates. It lists current stock information such as market cap and P/E ratio, alongside a peer comparison of other banking institutions. The forecast data was updated on …
SSBI
main company
Sharemaestro market context
Price below Trend Line
52 weeks +13.1%
Did Expanding Ivonescimab Into First-Line Bladder Cancer Just Shift Summit Therapeutics' (SMMT) Investment Narrative?
Summit Therapeutics (SMMT) has broadened its ivonescimab program by initiating a Phase II/III trial for first-line bladder cancer, adding to its growing list of target tumors. While this reinforces the long-term potential of ivonescimab, the near-term investment focus remains on the FDA's decision for …
SMMT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.0%
Summit Hotel Properties, Inc. (INN) Stock Price, News, Quote & History
This page provides a detailed overview of Summit Hotel Properties, Inc. (INN), including its current stock price, recent news, historical data, and financial performance. As of August 7, 2026, the stock closed at $6.49, down 2.84% for the day. The company, a REIT focused …
INN
main company
Sharemaestro market context
Trend signal active
52 weeks +17.1%
Amundi Invests $2.19 Million in Reynolds Consumer Products Inc. $REYN
Amundi initiated a significant position in Reynolds Consumer Products Inc. during the first quarter, investing $2.19 million to acquire 103,594 shares. The company recently surpassed quarterly earnings expectations and declared a quarterly dividend of $0.23 per share. Analysts maintain a consensus "Hold" rating for …
REYN
main company
Sharemaestro market context
Trend signal active
52 weeks +15.6%
Summit Hotel Properties, Inc. Q2 2026: Revenue $199M, EPS $0.04— 10-Q Summary
Summit Hotel Properties, Inc. reported its Q2 2026 financial results, achieving $199M in revenue and diluted EPS of $0.04, showcasing year-over-year growth in revenue and improved profitability compared to Q2 2025. Key factors included a 3.2% increase in revenue, a positive net income of …
INN
main company
Sharemaestro market context
Trend signal active
52 weeks +17.1%
Earnings call transcript: Summit Hotel beats Q2 2026 estimates but shares fall
Summit Hotel Properties (INN) exceeded Q2 2026 earnings expectations, reporting adjusted EPS of $0.04 against a forecast loss of $0.05, and revenue of $199.02 million, slightly above estimates. Despite raising its full-year guidance due to stronger hotel performance, the company's stock fell by 2.79% …
INN
main company
Sharemaestro market context
Trend signal active
52 weeks +17.1%
Press Release: SUMMIT HOTEL PROPERTIES REPORTS SECOND QUARTER 2026 RESULTS
This press release from Summit Hotel Properties reports their financial results for the second quarter of 2026. It provides key performance indicators and a summary of the company's financial health during that period.
INN
main company
Sharemaestro market context
Trend signal active
52 weeks +17.1%
News | Summit Hotels CEO: Second-quarter success about 'more than the World Cup'
Summit Hotel Properties CEO Jonathan Stanner reported strong second-quarter results, emphasizing that success extended beyond the FIFA World Cup due to a broad lift in business transient and group travel. The company saw meaningful revenue per available room and earnings growth in various urban …
INN
main company
Sharemaestro market context
Trend signal active
52 weeks +17.1%
Summit expands ivonescimab's challenge to Keytruda into bladder cancer
Summit Therapeutics is expanding its ivonescimab development beyond lung cancer by initiating the HARMONi-GU1 Phase II/III trial for bladder cancer. This trial will test ivonescimab plus Astellas/Pfizer's Padcev against Merck's Keytruda plus enfortumab vedotin for first-line treatment of advanced urothelial carcinoma. The company aims …
SMMT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.0%
Summit Therapeutics (SMMT) Could Be 52% Undervalued Following New Ivonescimab Trial Updates
Summit Therapeutics (SMMT) is currently assessed as 52% undervalued, with a fair value estimated at $28.36 against its closing price of $13.76. This valuation is largely based on ambitious assumptions regarding its ivonescimab program, which recently expanded with a new global Phase II/III bladder …
Sharemaestro market context Price below Trend Line 52 weeks -31.8% · Next-week setup negative 7.4%